Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 878 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Rectum Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants

NCT00617071
View directory record Official record
Conditions
Colorectal Cancer
Interventions
medical chart review, survey administration, fecal occult blood test, screening colonoscopy
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
50 Years to 74 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 25, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

NCT04873895
View directory record Official record
Conditions
Colorectal Neoplasms Malignant
Interventions
Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

NCT00113230
View directory record Official record
Conditions
Rectal Cancer
Interventions
Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 25, 2026, 4:41 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Promoting Equity for Cancer Screening and Follow-up

NCT04831827
View directory record Official record
Conditions
Colorectal (Colon or Rectal) Cancer
Interventions
IVR Reminder, Phone call from research team, EHR Portal message
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

NCT00625651
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions
Placebo, AMG 655, Modified FOLFOX6, Bevacizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
61
States / cities
Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 25, 2026, 4:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

NCT03741166
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
45 Years to 49 Years
Enrollment
871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Camarillo, California • Laguna Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 25, 2026, 4:41 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01740648
View directory record Official record
Conditions
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
trametinib, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
4
States / cities
St Louis, Missouri • Buffalo, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 25, 2026, 4:41 PM EDT
Withdrawn Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

NCT00025532
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
iodine I 131 monoclonal antibody CC49-deltaCH2
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00003799
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 25, 2026, 4:41 PM EDT
Terminated Phase 3 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

NCT04607668
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
Interventions
Trilaciclib, Placebo
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 25, 2026, 4:41 PM EDT
Withdrawn No phase listed Observational

Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

NCT05356585
View directory record Official record
Conditions
Colorectal Cancer, Rectal Cancer
Interventions
SignateraTM assay
Genetic
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 25, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

NCT00107315
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, capecitabine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

NCT00321685
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
107
States / cities
Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00005085
View directory record Official record
Conditions
Colorectal Cancer
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Atlanta, Georgia • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 25, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

NCT02425683
View directory record Official record
Conditions
Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
Regorafenib
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Including Dallas, TX, Ocala, FL, Denver, CO, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

NCT02130427
View directory record Official record
Conditions
Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions
CT scan
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 25, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

NCT00012246
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 25, 2026, 4:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Encorafenib, Cetuximab, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT06263088
View directory record Official record
Conditions
Gastrointestinal Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Esophageal Cancer, Stomach Cancer, Appendix Cancer, Pancreas Cancer, Liver Cancer, Neuroendocrine Tumors
Interventions
EQUITY GI
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00084591
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 25, 2026, 4:41 PM EDT
Active, not recruiting Phase 1 Interventional

Ultra-fractionated Radiotherapy for Rectal Cancer

NCT04677413
View directory record Official record
Conditions
Rectal Cancer
Interventions
Ultrafractionated radiotherapy for rectal cancer
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing and Evaluating Product Messaging

NCT04716010
View directory record Official record
Conditions
Cancer of Colon, Cancer of Rectum
Interventions
Control, Warning Labels, Tax, Combined Warning Labels and Tax
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
4,160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 25, 2026, 4:41 PM EDT